Intimation of completion of acquisition of Lannet by Aurobindo Pharma USA Inc, a wholly owned subsidiary of the Company.
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 30 Jun 2026, 09:54 AM IST · BSE ID: 246ff570-c1c2-400d-b7dd-407bba452288
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma's US subsidiary has completed buying Lannett Company, Inc., making it a new part of their business.
🤖 AI Summary
- Aurobindo Pharma USA Inc. completed the acquisition of Lannett Company, Inc., USA.
- Lannett officially became a wholly owned subsidiary of APUSA, effective June 29, 2026.
- Lannett will operate as Lannett Company LLC under Aurobindo Pharma USA Inc.
- More than 400 Lannett employees have been welcomed into the Aurobindo Pharma USA Inc. organization.
🏢 How This Affects the Company
The acquisition expands Aurobindo Pharma's presence and product portfolio in the US market through Lannett Company LLC.
The integration process will commence immediately, combining capabilities and resources and adding over 400 new employees to Aurobindo Pharma USA Inc.
👥 What This Means For Shareholders
✅
Action Required
No direct action is required by shareholders based on this acquisition completion intimation.
👤
Who Is Affected
Shareholders of Aurobindo Pharma Ltd will be affected as the company's US operations expand through the addition of Lannett Company LLC.
🔍
Management Signal
The completion signals management's commitment to strategic expansion and strengthening its presence in the US pharmaceutical market.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Future financial results — assess contribution from Lannett Company LLC operations.
Management commentary — obtain details on integration progress and synergies.
Market updates — track any further announcements regarding the combined entity's US operations.
LOW RISK
The filing confirms a completed acquisition, indicating reduced execution risk.
💡 Investor Takeaway
Aurobindo Pharma USA Inc. completed its acquisition of Lannett Company, Inc., USA, effective June 29, 2026, following US FTC approval. Lannett, with over 400 employees, now operates as Lannett Company LLC, a wholly owned subsidiary.
⚖️ Strengths & Concerns
✅ Positives
- Successful completion of the acquisition strengthens Aurobindo Pharma USA Inc.'s market position in the US pharmaceutical sector.
- Integration of over 400 Lannett employees enhances Aurobindo Pharma USA Inc.'s talent base and operational capabilities.
📅 Company Track Record
Aurobindo Pharma had previously intimated receipt of necessary approvals from the US Federal Trade Commission on June 19, 2026, for this Lannett acquisition, with closure expected in June 2026. This filing confirms the completion within the anticipated timeframe.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What event did Aurobindo Pharma Ltd disclose on June 30, 2026?
Aurobindo Pharma Ltd disclosed the successful completion of the acquisition of Lannett Company, Inc., USA, by its wholly owned subsidiary, Aurobindo Pharma USA Inc.
When did Lannett Company, Inc. become a subsidiary of Aurobindo Pharma USA Inc.?
Lannett Company, Inc. became a wholly owned subsidiary of Aurobindo Pharma USA Inc. effective June 29, 2026, and will operate as Lannett Company LLC.
How many employees from Lannett are joining Aurobindo Pharma USA Inc.?
More than 400 Lannett employees are being welcomed into the Aurobindo Pharma USA Inc. organization as part of the acquisition.
What regulatory approval was received for the Lannett acquisition?
Approval from the U.S. Federal Trade Commission was received on June 18, 2026, prior to the acquisition's completion.
Questions based on this BSE filing only. For information purposes.